Rheumatoid Arthritis
Conditions
Brief summary
Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease, characterized by symmetric poly-arthritis usually involving the small joints of the hands and feet. In addition, various extra-joint manifestations may develop. Several immunomodulating agents have been attempted in the treatment of RA without achieving satisfactory results. Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune diseases, which can be promoted by interleukin-2 (IL-2). The investigators hypothesized that low-dose IL-2 could be a novel therapy in active RA patients. This clinical study will test the efficacy and safety of low dose IL-2 treatment in RA. The investigators perform a single-centre, double-blind pilot trial with hrIL-2 in RA. The investigators evaluate the effectiveness and safeness of low-dose hrIL-2 for RA by randomized controlled study (hrIL-2 (N = 23) + Methotrexate (MTX)+ Loxoprofen versus placebo+MTX + Loxoprofen group (N = 24)).
Detailed description
Each RA patients (n=47) with DAS\>3.2 received low-dose IL-2+MTX+ Loxoprofen or placebo+MTX + Loxoprofen (active group: placebo group =1:1, 1 million units every other day subcutaneously (hrIL-2 1×106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3 cycles. The end points were safety and clinical and immunologic response.
Interventions
DRUGhrIL-2 active
hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
DRUGhrIL-2 placebo
hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
DRUGMTX
Methotrexate (oral administration)
DRUGFolic Acid
Folic Acid (oral administration)
DRUGLoxoprofen
Loxoprofen (oral administration)
Sponsors
Monash University
Beijing ShuangLu Pharmaceutical Co., Ltd.
Peking University People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male or female ≥18 and ≤70 years of age at time of screening * Diagnosed with rheumatoid arthritis * Must have active disease with DMARDs (Disease Modifying Anti-Rheumatic Drugs) except MTX, the doses had been stable for at least 3 months before baseline * Moderate or severe rheumatoid arthritis during screening, as defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-ESR) \> 3.2 * Have given written informed consent
Exclusion criteria
* Patient presenting or having a history of other inflammatory joint disease * Patient with ongoing or previous Stevens-Johnson syndrome, toxic epidermal necrolysis or erythema multiforme * Patient with significantly impaired bone marrow function or significant anaemia, leucopenia or thrombocytopenia due to causes or other than active rheumatoid arthritis * Persistent infection or severe infection within 3 months before enrollment, * Uncontrolled hypertension, uncontrolled diabetes, unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, terminal illness or other medical condition which, in the opinion of the investigator, would put the patient at risk to participate in the study, * Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult * Severe hypoproteinemia (e.g., in case of severe liver disease or nephrotic syndrome) with serum albumin \< 30 g/L * Moderate or severe impairment of renal function, as known by serum creatinine \> 133μmol/L (or 1.5 mg/dl) * Patient with history of recent and clinically significant drug or alcohol abuse * Impairment of liver function or persisting ALT (SGPT) elevations of more than 2-fold the upper limit of normal * Known HIV positive status * Known positive serology for hepatitis B or C * Patient with hypersensitivity to any of the excipients in the tablets of methotrexate * Pregnancy * Breastfeeding * Women of childbearing potential, except if they fulfill specific conditions, * Men wishing to father children during the course of the study or within the 24 months thereafter (or 3 month with the washout procedure) * Patient with a congenital or acquired severe immuno-deficiency, a history of cancer or lymphoproliferative disease, or any patient who has received total lymphoid irradiation. * Enrollment in any other clinical trial involving off-label use of an investigational drug or device, or enrollment in any other type of medical research * Any active infection (including chronic or localized infections) for which anti-infectives were indicated within 28 days prior to first investigational product dose * BMI(body mass index) under 18.5 kg/m2 or more than 30 kg/m2 * The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving DAS28 Remission. | week 24 | DAS 28 remission is defined by a disease activity score (28 joint) calculated using the erythrocyte sedimentation rate (DAS28-ESR) of less than 2.6 |
| Percentage of Participants Meeting the American College of Rheumatology 20% Response Criteria | week 12, week 24 | The assessments are based on a 20% or greater improvement from Baseline in the number of tender joints, a 20%, or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP). |
| The Change From Baseline of Clinical Disease Activity Index (CDAI) | week 12, week 24 | Clinical Disease Activity Index(CDAI), the minimum is 0, the maximum is 76. higher scores mean a worse outcome. The change of from baseline of CDAI, the minimum is -76, the maximum is 76. higher scores mean a worse outcome. |
| The Change From Baseline of Simplified Disease Activity Index (SDAI) | week 12, week 24 | Simplified Disease Activity Index(SDAI). the minimum is 0, the maximum is 96. higher scores mean worse outcome. The change from baseline of SDAI. the minimum is -96, the maximum is 96. higher scores mean worse outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Meeting the American College of Rheumatology 50% Response Criteria | week 12, week 24 | The assessments are based on a 50% or greater improvement from Baseline in the number of tender joints, a 50%, or more improvement in the number of swollen joints, and a 50% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP). |
| Percentage of Participants Meeting the American College of Rheumatology 70% Response Criteria | week 12, week 24 | The assessments are based on a 70% or greater improvement from Baseline in the number of tender joints, a 70%, or more improvement in the number of swollen joints, and a 70% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP). |
| Percentage of Participants Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice | week 12, week 24 | The 2011 ACR/EULAR remission criteria simplified for clinical practice is defined as:Tender Joint Count (TJC) ≤ 1, Swollen Joint Count (SJC) ≤ 1 and Patient's Global Assessment of Disease Activity (PtGADA) ≤ 1. |
| The Change From Baseline of a Health Assessment Questionnaire- Disability Index (HAQ-DI) | week 12, week 24 | The domains of the HAQ-DI are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. The total score ranges from 0 to 3 with lower scores meaning lower disability. The change from baseline of HAQ-DI, minimum is -3, the maximum is 3. higher scores mean a worse outcome. |
| The Scores of SF-36 Quetionnaire | week 12, week 24 | Score ranging from 0 to 100 with higher scores a better outcome. |
| Work Productivity Survey - Rheumatoid Arthritis [WPS-RA] | week 24 | The Arthritis interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference). The Arthritis interference in the last month with household work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference).higher scores mean a worse outcome. |
| Number of Participants With Adverse Events | Up to week 24 | adverse events includes injection site reactions, influenza-like symptoms, infection, fever, tumor, cardiovascular event, drug-induced liver and kidney damage. |
| C Reactive Protein (CRP) | week 12, week 24 | — |
| The Change From Baseline of Patient's Global Assessment of Disease Activity (PtGADA) | week 12, week 24 | VAS score from 0 to 100 for Patient's Global Assessment of Disease Activity Higher scores mean a worse outcome. The change from baseline of PtGADA, the minimum is -100, the maximum is 100. Higher scores mean a worse outcome. |
| The Change From Baseline of Physician's Global Assessment of Disease Activity (PhGADA) | week 12, week 24 | VAS score from 0 to 100 for Physician's Global Assessment of Disease Activity higher scores mean a worse outcome. The change from baseline, the minimum is -100, the maximum is 100. |
| The Change From Baseline of Patient's Assessment of Arthritis Pain (PtAAP) | week 12, week 24 | VAS score from 0 to 100 for Patient's Assessment of Arthritis Pain higher scores mean a worse outcome. The change from baseline of PtAAP, the minimum is -100, the maximum is 100. |
| Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | week 24 | In the last month, number of work days missed, number of work days with reduced productivity. In the last month, number of days with no household work, number of days with reduced household work productivity, number of days with hired outside help, number of days missed of family/social/leisure activities in the last month.higher scores mean a worse outcome. |
| Erythrocyte Sedimentation Rate (ESR) | week 12, week 24 | — |
| Percentage of CD4+ Treg Cells | week 12, week 24 | analysis regulatory CD4+ T(Treg) cells before and during IL-2 treatment. P values\<0.05 are considered statistically significant. |
| Percentage of Participants Achieving DAS28 Low Disease Activity. | week 12, week 24 | Low disease activity is defined by a disease activity score (28 joint) calculated using the erythrocyte sedimentation rate (DAS28-ESR) of less than 3.2 |
| Percentage of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response | week 12, week 24 | Good response is defined as: DAS28-ESR ≤ 3.2 and decrease from Baseline by \> 1.2. moderate response is defined as achievement of one of the following: DAS28-ESR ≤ 3.2 and decrease from Baseline \> 0.6 and ≤ 1.2 DAS28-ESR \> 3.2 and ≤ 5.1 and decrease from Baseline \> 0.6 DAS28-ESR \> 5.1 and decrease from Baseline \>1.2. |
Countries
China
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Experimental hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration) | 23 |
| Placebo Comparator hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration) | 24 |
| Total | 47 |
Baseline characteristics
| Characteristic | Experimental | Placebo Comparator | Total |
|---|---|---|---|
| Age, Continuous | 52.6 years STANDARD_DEVIATION 10.9 | 56.4 years STANDARD_DEVIATION 9.9 | 54.5 years STANDARD_DEVIATION 10.5 |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Sex/Gender, Customized Sex Female | 20 Participants | 20 Participants | 40 Participants |
| Sex/Gender, Customized Sex Male | 3 Participants | 4 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 11 / 23 | 9 / 24 |
| other Total, other adverse events | 9 / 23 | 8 / 24 |
| serious Total, serious adverse events | 2 / 23 | 1 / 24 |
Outcome results
Primary
Percentage of Participants Achieving DAS28 Remission.
DAS 28 remission is defined by a disease activity score (28 joint) calculated using the erythrocyte sedimentation rate (DAS28-ESR) of less than 2.6
Time frame: week 24
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Experimental | Percentage of Participants Achieving DAS28 Remission. | 6 Participants |
| Placebo Comparator | Percentage of Participants Achieving DAS28 Remission. | 6 Participants |
p-value: 0.53Chi-squared
Primary
Percentage of Participants Meeting the American College of Rheumatology 20% Response Criteria
The assessments are based on a 20% or greater improvement from Baseline in the number of tender joints, a 20%, or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
Time frame: week 12, week 24
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Experimental | Percentage of Participants Meeting the American College of Rheumatology 20% Response Criteria | week 24 | 13 Participants |
| Experimental | Percentage of Participants Meeting the American College of Rheumatology 20% Response Criteria | week 12 | 12 Participants |
| Placebo Comparator | Percentage of Participants Meeting the American College of Rheumatology 20% Response Criteria | week 24 | 13 Participants |
| Placebo Comparator | Percentage of Participants Meeting the American College of Rheumatology 20% Response Criteria | week 12 | 10 Participants |
p-value: 0.315Chi-squared
Primary
The Change From Baseline of Clinical Disease Activity Index (CDAI)
Clinical Disease Activity Index(CDAI), the minimum is 0, the maximum is 76. higher scores mean a worse outcome. The change of from baseline of CDAI, the minimum is -76, the maximum is 76. higher scores mean a worse outcome.
Time frame: week 12, week 24
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Experimental | The Change From Baseline of Clinical Disease Activity Index (CDAI) | week 24 | -17.5 score on a scale |
| Experimental | The Change From Baseline of Clinical Disease Activity Index (CDAI) | week 12 | -15.0 score on a scale |
| Placebo Comparator | The Change From Baseline of Clinical Disease Activity Index (CDAI) | week 24 | -11 score on a scale |
| Placebo Comparator | The Change From Baseline of Clinical Disease Activity Index (CDAI) | week 12 | -8.0 score on a scale |
p-value: 0.018Mixed Models Analysis
Primary
The Change From Baseline of Simplified Disease Activity Index (SDAI)
Simplified Disease Activity Index(SDAI). the minimum is 0, the maximum is 96. higher scores mean worse outcome. The change from baseline of SDAI. the minimum is -96, the maximum is 96. higher scores mean worse outcome.
Time frame: week 12, week 24
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Experimental | The Change From Baseline of Simplified Disease Activity Index (SDAI) | week 24 | -19.0 score on a scale |
| Experimental | The Change From Baseline of Simplified Disease Activity Index (SDAI) | week 12 | -16.9 score on a scale |
| Placebo Comparator | The Change From Baseline of Simplified Disease Activity Index (SDAI) | week 24 | -12.1 score on a scale |
| Placebo Comparator | The Change From Baseline of Simplified Disease Activity Index (SDAI) | week 12 | -9.2 score on a scale |
p-value: 0.015Mixed Models Analysis
Secondary
C Reactive Protein (CRP)
Time frame: week 12, week 24
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Experimental | C Reactive Protein (CRP) | week 24 | 21.6 mg/L | Standard Deviation 20.83 |
| Experimental | C Reactive Protein (CRP) | week 12 | 9.5 mg/L | Standard Deviation 9 |
| Placebo Comparator | C Reactive Protein (CRP) | week 24 | 15.32 mg/L | Standard Deviation 14.74 |
| Placebo Comparator | C Reactive Protein (CRP) | week 12 | 7.8 mg/L | Standard Deviation 7.2 |
p-value: 0.422Mixed Models Analysis
Secondary
Erythrocyte Sedimentation Rate (ESR)
Time frame: week 12, week 24
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Experimental | Erythrocyte Sedimentation Rate (ESR) | Week 24 | 43.3 millimeter/hour | Standard Deviation 25.9 |
| Experimental | Erythrocyte Sedimentation Rate (ESR) | Week 12 | 29.6 millimeter/hour | Standard Deviation 25.6 |
| Placebo Comparator | Erythrocyte Sedimentation Rate (ESR) | Week 24 | 36.8 millimeter/hour | Standard Deviation 24.9 |
| Placebo Comparator | Erythrocyte Sedimentation Rate (ESR) | Week 12 | 28.3 millimeter/hour | Standard Deviation 21.6 |
p-value: 0.881Mixed Models Analysis
Secondary
Number of Participants With Adverse Events
adverse events includes injection site reactions, influenza-like symptoms, infection, fever, tumor, cardiovascular event, drug-induced liver and kidney damage.
Time frame: Up to week 24
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Experimental | Number of Participants With Adverse Events | 11 Participants |
| Placebo Comparator | Number of Participants With Adverse Events | 9 Participants |
p-value: 0.474Chi-squared
Secondary
Percentage of CD4+ Treg Cells
analysis regulatory CD4+ T(Treg) cells before and during IL-2 treatment. P values\<0.05 are considered statistically significant.
Time frame: week 12, week 24
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Experimental | Percentage of CD4+ Treg Cells | Week 24 | 6.94 percentage of CD4+ T cells |
| Experimental | Percentage of CD4+ Treg Cells | Week 12 | 6.84 percentage of CD4+ T cells |
| Placebo Comparator | Percentage of CD4+ Treg Cells | Week 24 | 6.46 percentage of CD4+ T cells |
| Placebo Comparator | Percentage of CD4+ Treg Cells | Week 12 | 5.37 percentage of CD4+ T cells |
p-value: 0.665Mixed Models Analysis
Secondary
Percentage of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response
Good response is defined as: DAS28-ESR ≤ 3.2 and decrease from Baseline by \> 1.2. moderate response is defined as achievement of one of the following: DAS28-ESR ≤ 3.2 and decrease from Baseline \> 0.6 and ≤ 1.2 DAS28-ESR \> 3.2 and ≤ 5.1 and decrease from Baseline \> 0.6 DAS28-ESR \> 5.1 and decrease from Baseline \>1.2.
Time frame: week 12, week 24
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Experimental | Percentage of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response | week 24 | 17 Participants |
| Experimental | Percentage of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response | week 12 | 15 Participants |
| Placebo Comparator | Percentage of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response | week 24 | 20 Participants |
| Placebo Comparator | Percentage of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response | week 12 | 14 Participants |
p-value: 0.616Chi-squared
Secondary
Percentage of Participants Achieving DAS28 Low Disease Activity.
Low disease activity is defined by a disease activity score (28 joint) calculated using the erythrocyte sedimentation rate (DAS28-ESR) of less than 3.2
Time frame: week 12, week 24
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Experimental | Percentage of Participants Achieving DAS28 Low Disease Activity. | week 24 | 8 Participants |
| Experimental | Percentage of Participants Achieving DAS28 Low Disease Activity. | week 12 | 7 Participants |
| Placebo Comparator | Percentage of Participants Achieving DAS28 Low Disease Activity. | week 24 | 9 Participants |
| Placebo Comparator | Percentage of Participants Achieving DAS28 Low Disease Activity. | week 12 | 7 Participants |
p-value: 0.616Chi-squared
Secondary
Percentage of Participants Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice
The 2011 ACR/EULAR remission criteria simplified for clinical practice is defined as:Tender Joint Count (TJC) ≤ 1, Swollen Joint Count (SJC) ≤ 1 and Patient's Global Assessment of Disease Activity (PtGADA) ≤ 1.
Time frame: week 12, week 24
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Experimental | Percentage of Participants Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice | week 24 | 2 Participants |
| Experimental | Percentage of Participants Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice | week 12 | 0 Participants |
| Placebo Comparator | Percentage of Participants Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice | week 24 | 1 Participants |
| Placebo Comparator | Percentage of Participants Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice | week 12 | 0 Participants |
p-value: 0.565Chi-squared
Secondary
Percentage of Participants Meeting the American College of Rheumatology 50% Response Criteria
The assessments are based on a 50% or greater improvement from Baseline in the number of tender joints, a 50%, or more improvement in the number of swollen joints, and a 50% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
Time frame: week 12, week 24
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Experimental | Percentage of Participants Meeting the American College of Rheumatology 50% Response Criteria | week 24 | 10 Participants |
| Experimental | Percentage of Participants Meeting the American College of Rheumatology 50% Response Criteria | weed 12 | 6 Participants |
| Placebo Comparator | Percentage of Participants Meeting the American College of Rheumatology 50% Response Criteria | week 24 | 8 Participants |
| Placebo Comparator | Percentage of Participants Meeting the American College of Rheumatology 50% Response Criteria | weed 12 | 3 Participants |
p-value: 0.2Chi-squared
Secondary
Percentage of Participants Meeting the American College of Rheumatology 70% Response Criteria
The assessments are based on a 70% or greater improvement from Baseline in the number of tender joints, a 70%, or more improvement in the number of swollen joints, and a 70% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
Time frame: week 12, week 24
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Experimental | Percentage of Participants Meeting the American College of Rheumatology 70% Response Criteria | week 24 | 4 Participants |
| Experimental | Percentage of Participants Meeting the American College of Rheumatology 70% Response Criteria | week 12 | 2 Participants |
| Placebo Comparator | Percentage of Participants Meeting the American College of Rheumatology 70% Response Criteria | week 24 | 2 Participants |
| Placebo Comparator | Percentage of Participants Meeting the American College of Rheumatology 70% Response Criteria | week 12 | 0 Participants |
p-value: 0.373Chi-squared
Secondary
The Change From Baseline of a Health Assessment Questionnaire- Disability Index (HAQ-DI)
The domains of the HAQ-DI are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. The total score ranges from 0 to 3 with lower scores meaning lower disability. The change from baseline of HAQ-DI, minimum is -3, the maximum is 3. higher scores mean a worse outcome.
Time frame: week 12, week 24
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Experimental | The Change From Baseline of a Health Assessment Questionnaire- Disability Index (HAQ-DI) | week 24 | -0.63 score on a scale |
| Experimental | The Change From Baseline of a Health Assessment Questionnaire- Disability Index (HAQ-DI) | week 12 | -0.50 score on a scale |
| Placebo Comparator | The Change From Baseline of a Health Assessment Questionnaire- Disability Index (HAQ-DI) | week 24 | -0.38 score on a scale |
| Placebo Comparator | The Change From Baseline of a Health Assessment Questionnaire- Disability Index (HAQ-DI) | week 12 | -0.25 score on a scale |
p-value: 0.221Wilcoxon (Mann-Whitney)
Secondary
The Change From Baseline of Patient's Assessment of Arthritis Pain (PtAAP)
VAS score from 0 to 100 for Patient's Assessment of Arthritis Pain higher scores mean a worse outcome. The change from baseline of PtAAP, the minimum is -100, the maximum is 100.
Time frame: week 12, week 24
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Experimental | The Change From Baseline of Patient's Assessment of Arthritis Pain (PtAAP) | week 24 | -57.5 score on a scale |
| Experimental | The Change From Baseline of Patient's Assessment of Arthritis Pain (PtAAP) | week 12 | -57.1 score on a scale |
| Placebo Comparator | The Change From Baseline of Patient's Assessment of Arthritis Pain (PtAAP) | week 24 | -33.3 score on a scale |
| Placebo Comparator | The Change From Baseline of Patient's Assessment of Arthritis Pain (PtAAP) | week 12 | -27.3 score on a scale |
p-value: 0.156Wilcoxon (Mann-Whitney)
Secondary
The Change From Baseline of Patient's Global Assessment of Disease Activity (PtGADA)
VAS score from 0 to 100 for Patient's Global Assessment of Disease Activity Higher scores mean a worse outcome. The change from baseline of PtGADA, the minimum is -100, the maximum is 100. Higher scores mean a worse outcome.
Time frame: week 12, week 24
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Experimental | The Change From Baseline of Patient's Global Assessment of Disease Activity (PtGADA) | week 24 | -57.5 score on a scale |
| Experimental | The Change From Baseline of Patient's Global Assessment of Disease Activity (PtGADA) | week 12 | -57.1 score on a scale |
| Placebo Comparator | The Change From Baseline of Patient's Global Assessment of Disease Activity (PtGADA) | week 24 | -33.3 score on a scale |
| Placebo Comparator | The Change From Baseline of Patient's Global Assessment of Disease Activity (PtGADA) | week 12 | -33.3 score on a scale |
p-value: 0.055Wilcoxon (Mann-Whitney)
Secondary
The Change From Baseline of Physician's Global Assessment of Disease Activity (PhGADA)
VAS score from 0 to 100 for Physician's Global Assessment of Disease Activity higher scores mean a worse outcome. The change from baseline, the minimum is -100, the maximum is 100.
Time frame: week 12, week 24
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Experimental | The Change From Baseline of Physician's Global Assessment of Disease Activity (PhGADA) | week 24 | -58.3 score on a scale |
| Experimental | The Change From Baseline of Physician's Global Assessment of Disease Activity (PhGADA) | week 12 | -57.1 score on a scale |
| Placebo Comparator | The Change From Baseline of Physician's Global Assessment of Disease Activity (PhGADA) | week 24 | -44.4 score on a scale |
| Placebo Comparator | The Change From Baseline of Physician's Global Assessment of Disease Activity (PhGADA) | week 12 | -25.0 score on a scale |
p-value: 0.039Wilcoxon (Mann-Whitney)
Secondary
The Scores of SF-36 Quetionnaire
Score ranging from 0 to 100 with higher scores a better outcome.
Time frame: week 12, week 24
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Experimental | The Scores of SF-36 Quetionnaire | week 24 | 15.29 score on a scale |
| Experimental | The Scores of SF-36 Quetionnaire | week 12 | 24.32 score on a scale |
| Placebo Comparator | The Scores of SF-36 Quetionnaire | week 24 | 6.90 score on a scale |
| Placebo Comparator | The Scores of SF-36 Quetionnaire | week 12 | 27.25 score on a scale |
p-value: 0.085Wilcoxon (Mann-Whitney)
Secondary
Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]
The Arthritis interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference). The Arthritis interference in the last month with household work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference).higher scores mean a worse outcome.
Time frame: week 24
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Experimental | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA] | rate of Arthritis interference | 3 units on a scale |
| Experimental | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA] | Rate of arthritis interference with household work | 5 units on a scale |
| Placebo Comparator | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA] | rate of Arthritis interference | 2 units on a scale |
| Placebo Comparator | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA] | Rate of arthritis interference with household work | 5 units on a scale |
p-value: 0.74Wilcoxon (Mann-Whitney)
Secondary
Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2
In the last month, number of work days missed, number of work days with reduced productivity. In the last month, number of days with no household work, number of days with reduced household work productivity, number of days with hired outside help, number of days missed of family/social/leisure activities in the last month.higher scores mean a worse outcome.
Time frame: week 24
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Experimental | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | number of work days with reduced productivity | 3.5 days |
| Experimental | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | number of work days missed | 0 days |
| Experimental | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | Household work days missed due to arthritis | 0 days |
| Experimental | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | Days with household work productivity reduced | 15 days |
| Experimental | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | Days with activities missed due to arthritis | 5 days |
| Experimental | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | Days with outside help hired due to arthritis | 0 days |
| Placebo Comparator | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | Days with activities missed due to arthritis | 0 days |
| Placebo Comparator | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | number of work days with reduced productivity | 0 days |
| Placebo Comparator | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | Days with household work productivity reduced | 12 days |
| Placebo Comparator | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | number of work days missed | 0 days |
| Placebo Comparator | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | Days with outside help hired due to arthritis | 0 days |
| Placebo Comparator | Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2 | Household work days missed due to arthritis | 0 days |